As of Sep 28
| -0.52 / -2.35%|
The 12 analysts offering 12-month price forecasts for Myriad Genetics Inc have a median target of 21.50, with a high estimate of 42.00 and a low estimate of 18.00. The median estimate represents a -0.37% decrease from the last price of 21.58.
The current consensus among 17 polled investment analysts is to Hold stock in Myriad Genetics Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.